Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc., saying the US company is using “deceptive marketing” to sell copycat versions of its obesity blockbuster Wegovy.
Hims, a telehealth platform, wasn’t stepping back enough from its practice of mass marketing compounded versions of the weight-loss medicine, said Dave Moore, the executive vice president of Novo’s US operations.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.